<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">12626</article-id><article-id pub-id-type="doi">10.7554/eLife.12626</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Registered Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-40519"><name><surname>Fiehn</surname><given-names>Oliver</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45064"><name><surname>Showalter</surname><given-names>Megan Reed</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-45065"><name><surname>Schaner-Tooley</surname><given-names>Christine E</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><collab>Reproducibility Project: Cancer Biology</collab><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">West Coast Metabolomics Center</institution>, <institution>University of California, Davis</institution>, <addr-line><named-content content-type="city">Davis</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution>University of Louisville School of Medicine</institution>, <addr-line><named-content content-type="city">Louisville</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Tyler</surname><given-names>Jessica K</given-names></name><role>Reviewing editor</role><aff id="aff3"><institution>Weill Cornell Medical College</institution>, <country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Iorns</surname><given-names>Elizabeth</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Gunn</surname><given-names>William</given-names></name><aff><institution>Mendeley</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Tan</surname><given-names>Fraser</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Lomax</surname><given-names>Joelle</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Williams</surname><given-names>Stephen</given-names></name><aff><institution>Center for Open Science</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>Virginia</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Perfito</surname><given-names>Nicole</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Errington</surname><given-names>Timothy</given-names></name><aff><institution>Center for Open Science</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>Virginia</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>stephen@cos.io</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>02</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e12626</elocation-id><history><date date-type="received"><day>30</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>13</day><month>02</month><year>2016</year></date><fn><p><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Wise</surname><given-names>DR</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Coller</surname><given-names>HA</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Fantin</surname><given-names>VR</given-names></name><name><surname>Hedvat</surname><given-names>CV</given-names></name><name><surname>Perl</surname><given-names>AE</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Carroll</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>SM</given-names></name><name><surname>Sharp</surname><given-names>KA</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group> . <day>16</day><month>03</month><year iso-8601-date="2010">2010</year> . <article-title>The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate</article-title> .<source>Cancer Cell</source> . <volume>17</volume> . <fpage>225</fpage> – <lpage>234</lpage> . doi: <pub-id pub-id-type="doi">10.1016/j.ccr.2010.01.020</pub-id> .</mixed-citation> </p></fn></history><permissions><copyright-statement>© 2016, Fiehn et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Fiehn et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-12626-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.12626.001</object-id><p>The <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/home/">Reproducibility Project: Cancer Biology</ext-link> seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/studies/">citations and Altmetric scores</ext-link> (<xref ref-type="bibr" rid="bib3">Errington et al., 2014</xref>). This Registered Report describes the proposed replication plan of key experiments from “The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate” by Ward and colleagues, published in Cancer Cell in 2010 (<xref ref-type="bibr" rid="bib16">Ward et al., 2010</xref>). The experiments that will be replicated are those reported in Figures 2, 3 and 5. Ward and colleagues demonstrate the mutations in isocitrate dehydrogenase 2 (<italic>IDH2</italic>), commonly found in acute myeloid leukemia (AML), abrogate the enzyme’s wild-type activity and confer to the mutant neomorphic activity that produces the oncometabolite 2-hydroxyglutarate (2-HG) (Figures 2 and 3). They then show that elevated levels of 2-HG are correlated with mutations in <italic>IDH1</italic> and <italic>IDH2</italic> in AML patient samples (Figure 5). The Reproducibility Project: Cancer Biology is a collaboration between the <ext-link ext-link-type="uri" xlink:href="http://centerforopenscience.org/">Center for Open Science</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.scienceexchange.com/">Science Exchange</ext-link> and the results of the replications will be published by <italic>eLife</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.12626.001">http://dx.doi.org/10.7554/eLife.12626.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>Reproducibility Project: Cancer Biology</kwd><kwd>methodology</kwd><kwd>IDH1</kwd><kwd>IDH2</kwd><kwd>acute myeloid leukemia</kwd><kwd>2-HG</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Human</kwd></kwd-group><funding-group><funding-statement>The Reproducibility Project: Cancer Biology is funded by the Laura and John Arnold Foundation, provided to the Center for Open Science in collaboration with Science Exchange. The funder had no role in study design or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Mutations in the metabolic enzymes isocitrate dehydrogenase 1 (<italic>IDH1</italic>) and <italic>IDH2</italic> genes, which catalyze the production of α-ketoglutarate (α-KG) from isocitrate, have been associated with numerous forms of cancer (<xref ref-type="bibr" rid="bib9">Krell et al., 2013</xref>) leading to exploration of how changes in their function could be linked to the development of tumors. All known mutations alter key residues in both proteins that decrease the enzyme’s affinity for isocitrate, leading to the theory that the loss of IDH function perturbs the equilibrium of α-KG, negatively affecting various α-KG dependent enzymes (<xref ref-type="bibr" rid="bib18">Zhao et al., 2009</xref>). However, work from the Thompson group determined that the tumor-associated mutations actually created a neomorphic function; rather than catalyzing the production of α-KG, mutant IDH proteins produce the oncometabolite 2-hydroxyglutarate (2-HG) (<xref ref-type="bibr" rid="bib14">Ward et al., 2012</xref>). Dang and colleagues first described this neomorphic function and demonstrated a correlation between 2-HG levels and glioma samples harboring <italic>IDH</italic> mutations (<xref ref-type="bibr" rid="bib2">Dang et al., 2009</xref>). In their 2010 Cancer Cell paper, Ward and colleagues further confirm these findings and extend the association of 2-HG levels and <italic>IDH</italic> mutations to acute myeloid leukemia (AML) (<xref ref-type="bibr" rid="bib16">Ward et al., 2010</xref>).</p><p>In Figure 2, Ward and colleagues transfected 293T cells with either wild type or mutant forms of <italic>IDH2</italic>. They assessed cell lysates for their ability to generate NDPH in the presence of isocitrate (Figure 2A) or to consume NADPH in the presence of α-KG (Figure 2B). Their data indicated that cells transfected with IDH2<sup>WT</sup> generated NADPH in the presence of isocitrate, and did not consume much NADPH in the presence of α-KG, consistent with its canonical function of converting isocitrate to α-KG. However, IDH2<sup>R172K</sup> displayed the opposite effect, indicating that it was able to consume NADPH in an α-KG dependent manner. These data were the first suggesting that the mutant form of IDH2 might have a neomorphic function. This key experiment will be replicated in Protocol 1.</p><p>In Figure 3, Ward and colleagues use gas-chromatography mass spectrometry (GC-MS) to identify a novel function of IDH2<sup>R172K</sup>. They identified a unique peak in the lysates of cells transfected with IDH2<sup>R172K</sup> that corresponded to the retention time of the metabolite 2-hydroxyglutarate (2-HG). They confirmed the metabolite identity by mass spectrometry. These data provide evidence that the mutant form of IDH2 leads to 2-HG production. This key experiment will be replicated in Protocol 2.</p><p>In Figure 5, Ward and colleagues examined the correlation between AML patient samples carrying <italic>IDH</italic> mutations and the levels of 2-HG found in those samples. They showed that patient samples carrying <italic>IDH</italic> mutations contained higher levels of 2-HG than samples from patients with WT <italic>IDH</italic> genes. This key experiment will be replicated in Protocol 3.</p><p>Several groups’ work has supported the results of Ward and colleagues, who themselves confirmed and extended their initial findings in subsequent reports (<xref ref-type="bibr" rid="bib14">Ward et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">2013</xref>). Leonardi and colleagues confirmed that mutant forms of <italic>IDH</italic>, specifically <italic>IDH1</italic>, did not perform the canonical forward reaction converting isocitrate to α-KG (<xref ref-type="bibr" rid="bib10">Leonardi et al., 2012</xref>). Using magnetic resonance spectroscopy, Izquierdo-Garcia and colleagues confirmed that transfection of cells with mutant <italic>IDH</italic> forms increased the levels of 2-HG (<xref ref-type="bibr" rid="bib6">Izquierdo-Garcia et al., 2015</xref>), while Jin and colleagues demonstrated similar findings for <italic>IDH1</italic> and <italic>IDH2</italic> mutants (<xref ref-type="bibr" rid="bib7">Jin et al., 2011</xref>). Evaluating 2-HG levels in astrocytomas and gliomas harboring various <italic>IDH1</italic> mutations, Pusch and colleagues also showed that any mutations in <italic>IDH1</italic> correlated with increased levels of 2-HG in human patient samples (<xref ref-type="bibr" rid="bib12">Pusch et al., 2014</xref>), a trend also observed by Juratli and colleagues (<xref ref-type="bibr" rid="bib8">Juratli et al., 2013</xref>).</p><p>Discovery of IDH neomorphic function, resulting in the production of the 'oncometabolite' 2-HG, opened many avenues of research into how the production of excess 2-HG could impact tumorigenesis. Figueroa and colleagues expanded upon the foundation laid by Ward and colleagues and determined that excess 2-HG was correlated with changes in global methylation patterns (<xref ref-type="bibr" rid="bib5">Figueroa et al., 2010</xref>). Xu and colleagues showed that 2-HG was able to competitively inhibit many α-KG dependent enzymes, including several histone demethylases, and that exogenous 1-HG was able to inhibit histone demethylation (<xref ref-type="bibr" rid="bib17">Xu et al., 2011</xref>). Lu and colleagues also observed this correlation between 2-HG levels and perturbations in global histone methylation patterns, and went on to show that this resulted in impaired cellular differentiation (<xref ref-type="bibr" rid="bib11">Lu et al., 2012</xref>).</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><p>Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors.</p><sec id="s2-1"><title>Protocol 1: Assessing the α-ketoglutarate dependent NADPH consumption of wild-type or mutant IDH2</title><p>In this protocol, 293T cells are transfected with empty vector, IDH2<sup>WT</sup>, or IDH2<sup>R172K</sup>. Lysates are generated from these cells and their ability to produce NADPH from NADP+ and isocitrate is assayed (Figure 2A). The same lysates are also assayed for their ability to consume NADPH in the presence of 0.5 mM α-ketoglutarate (α-KG) (Figure 2B). Expression of the transfected protein will be confirmed by Western blot (Figure 2C).</p><sec id="s2-1-1"><title>Sampling</title><p>Oxidative and reductive activity (Figures 2A and B):</p><list list-type="bullet"><list-item><p>Experiment has three conditions. Each will be performed with seven biological replicates and three technical replicates of each condition at each time point for a final power of at least 80%.<list list-type="simple"><list-item><p><list list-type="bullet"><list-item><p>Condition 1: 293T cells expressing <italic>IDH2<sup>WT</sup></italic></p></list-item><list-item><p>Condition 2: 293T cells expressing <italic>IDH2<sup>R172K</sup></italic></p></list-item><list-item><p>Condition 3: 293T cells expressing empty pCDNA3 vector</p></list-item></list></p></list-item><list-item><p>o Each lysate will be assessed for cell’s ability to reduce NADP<sup>+</sup> and oxidate NADPH</p></list-item><list-item><p>o See Power Calculations section for details.</p></list-item></list></p></list-item></list><p>Confirmatory Western Blot (Figure 2C)</p><list list-type="bullet"><list-item><p>This is a quality control experiment and is not being powered to detect a specific effect size. Western blots will be performed alongside each biological replicate.</p></list-item><list-item><p>Western blotting of each lysate will be performed for the following proteins<list list-type="bullet"><list-item><p>IDH2</p></list-item><list-item><p>IDH1</p></list-item><list-item><p>Actin [additional]</p></list-item></list></p></list-item></list></sec><sec id="s2-1-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>293T cells</td><td>Cells</td><td>ATCC</td><td>CRL-3216</td><td>Original source unspecified</td></tr><tr><td>Dulbecco’s modified <break/>Eagle’s medium (DMEM)</td><td>Media</td><td>Invitrogen</td><td>11965118</td><td>Original unspecified</td></tr><tr><td>FBS</td><td>Reagent</td><td>Hyclone</td><td>SH30071.03</td><td>Replaces FBS from CellGro</td></tr><tr><td>IDH2<sup>WT</sup> ORF in pCMV6</td><td>Plasmid</td><td>Origene</td><td>RC201152</td><td/></tr><tr><td>IDH2<sup>R172K</sup> ORF in pCMV6</td><td>Plasmid</td><td>Origene</td><td>RC400103</td><td/></tr><tr><td>pCDNA3</td><td>Plasmid</td><td>Invitrogen</td><td>V790-20</td><td/></tr><tr><td>Lipofectamine 2000</td><td>Reagent</td><td>Invitrogen</td><td>11668027</td><td/></tr><tr><td>M-Per Mammalian protein <break/>extraction reagent</td><td>Reagent</td><td>Pierce</td><td>78503</td><td/></tr><tr><td>Aprotinin</td><td>Reagent</td><td>Sigma</td><td>248614</td><td rowspan="4">Original protease <break/>inhibitor cocktail <break/>unspecified</td></tr><tr><td>AEBSF</td><td>Reagent</td><td>EMD Millipore</td><td>101500-100MG</td></tr><tr><td>Leupeptin</td><td>Reagent</td><td>Sigma</td><td>L2884-100mg</td></tr><tr><td>Pepstatin A</td><td>Reagent</td><td>EMD Millipore</td><td>516481-100MG</td></tr><tr><td>NaOV</td><td>Reagent</td><td>Sigma</td><td>450243-50G</td><td rowspan="2">Original unspecified</td></tr><tr><td>NaF</td><td>Reagent</td><td>Sigma</td><td>215309-50G</td></tr><tr><td>Sonicator</td><td>Equipment</td><td>VCR</td><td>75HT</td><td>Original unspecified</td></tr><tr><td>Refrigerated <break/>microcentrifuge</td><td>Equipment</td><td>Labnet International, Inc</td><td>PrismR</td><td>Original unspecified</td></tr><tr><td>Tris-HCl</td><td>Reagent</td><td>BioRad</td><td>BR0011</td><td>Original unspecified</td></tr><tr><td>MnCl2</td><td>Reagent</td><td>M87-100</td><td>Fisher</td><td>Original unspecified</td></tr><tr><td>EDTA</td><td>Reagent</td><td>VWR</td><td>EM-4050</td><td>Original unspecified</td></tr><tr><td>ß-NADP+</td><td>Reagent</td><td>MP Biomedicals</td><td>ICN10116680</td><td>Original unspecified</td></tr><tr><td>ß-NADPH</td><td>Reagent</td><td>Sigma</td><td>10107824001</td><td>Original unspecified</td></tr><tr><td>D-(+)-threo-isocitrate</td><td>Reagent</td><td>Sigma</td><td>I1252</td><td/></tr><tr><td>Spectrophotometer</td><td>Instrument</td><td>Molecular Devices</td><td>Filter Max F5 Multi-mode Microplate Reader</td><td>Original unspecified</td></tr><tr><td>6-well tissue <break/>culture plates</td><td>Materials</td><td>E&amp; K Scientific</td><td>27160</td><td>Original unspecified</td></tr><tr><td>96 well plates</td><td>Materials</td><td>Fisher (Costar)</td><td>07-200-656</td><td>Original unspecified</td></tr><tr><td>Tric-HCl</td><td>Reagent</td><td>BioRad</td><td>BR0011</td><td>Original unspecified</td></tr><tr><td>Glycerol</td><td>Reagent</td><td>VWR</td><td>EM-4760</td><td>Original unspecified</td></tr><tr><td>ß-mercaptoethanol</td><td>Reagent</td><td>Sigma</td><td>M6250-250mL</td><td>Original unspecified</td></tr><tr><td>Sodium dodecyl sulfate (SDS)</td><td>Reagent</td><td>Sigma</td><td>L3771-100G</td><td>Original unspecified</td></tr><tr><td>Bromophenol blue</td><td>Reagent</td><td>Sigma</td><td>B0126-25G</td><td>Original unspecified</td></tr><tr><td>Protogel</td><td>Reagent</td><td>Fisher/National Diagnostics</td><td>50-899-90119</td><td>Original unspecified</td></tr><tr><td>APS</td><td>Reagent</td><td>Sigma</td><td>248614</td><td>Original unspecified</td></tr><tr><td>TEMED</td><td>Reagent</td><td>Fisher</td><td>BP150-100</td><td>Original unspecified</td></tr><tr><td>nitrocellulose</td><td>Materials</td><td>BioRad</td><td>162-0112</td><td>Original unspecified</td></tr><tr><td>Anti-IDH2 antibody <break/>(mouse monoclonal)</td><td>Primary Antibody</td><td>Abcam</td><td>ab55271</td><td/></tr><tr><td>Anti-IDH1 antibody <break/>(goat polyclonal)</td><td>Primary Antibody</td><td>Santa Cruz</td><td>sc49996</td><td/></tr><tr><td>Anti-Actin antibody <break/>(rabbit monoclonal)- <break/>HRP conjugated</td><td>Primary Antibody</td><td>Cell Signaling</td><td>12620</td><td>Not included in original.</td></tr><tr><td>ECL Mouse IgG, <break/>HRP-linked whole Ab <break/>(from sheep)</td><td>Secondary Antibody</td><td>GE Healthcare</td><td>NA931V</td><td/></tr><tr><td>HRP conjugated rabbit <break/>anti-goat antibody</td><td>Secondary Antibody</td><td>Invitrogen</td><td>811620</td><td>Original unspecified</td></tr><tr><td rowspan="2">Protein ladders</td><td rowspan="2">Reagent</td><td>Cell Signaling Tech.</td><td>7727L</td><td>Original unspecified</td></tr><tr><td>Gold Biotech</td><td>p007-1500</td><td>Original unspecified</td></tr><tr><td>ECL reagent</td><td>Reagent</td><td>Fisher Scientific</td><td>PI34096</td><td>Original unspecified</td></tr><tr><td>Endo-free maxiprep kit</td><td>Reagent</td><td>Qiagen</td><td>12362</td><td>Original unspecified</td></tr><tr><td>α-ketoglutarate</td><td>Reagent</td><td>Sigma</td><td>75892-25G</td><td>Original unspecified</td></tr><tr><td>DC Protein Assay Kit</td><td>Kit</td><td>BioRad</td><td>5000112</td><td>Original unspecified</td></tr><tr><td>Alpha innotech imager</td><td>Equipment</td><td>Alpha Innotech</td><td>Alphaimager 2200</td><td/></tr><tr><td>sodium azide</td><td>Reagent</td><td>Sigma</td><td>S2002-5G</td><td>Original Unspecified</td></tr><tr><td>Ponceau stain</td><td>Reagent</td><td>Quality Biological</td><td>50-751-6798</td><td>Additional reagent</td></tr></tbody></table></table-wrap></sec><sec id="s2-1-3"><title>Procedure</title><sec id="s7"><title>Notes</title><list list-type="bullet"><list-item><p>293T cells are grown in DMEM supplemented with 10% FBS at 37°C in 5% CO<sub>2</sub></p></list-item><list-item><p>Cells will be sent for STR profiling and mycoplasma testing.</p></list-item></list><list list-type="order"><list-item><p>Confirm insert identity by sequencing.<list list-type="alpha-lower"><list-item><p>Origene clones are shipped with two sequencing primers.</p></list-item></list></p></list-item><list-item><p>Sub-clone IDH2<sup>WT</sup> and IDH2<sup>R172K</sup> from the Origene pCMV6-Entry vectors into pcDNA3.<list list-type="alpha-lower"><list-item><p>Confirm insert identity by sequencing.</p></list-item><list-item><p>Confirm vector integrity by agarose gel electrophoresis.</p></list-item></list></p></list-item><list-item><p>Grow up and use an endo-free maxiprep kit to prep the following vectors:<list list-type="alpha-lower"><list-item><p>pcDNA3</p></list-item><list-item><p>pcDNA3-IDH2<sup>WT</sup></p></list-item><list-item><p>pcDNA3-IDH2<sup>R172K</sup></p></list-item></list></p></list-item><list-item><p>Seed 0.25-1x10<sup>6</sup> 293T cells per well of a 6-well plate in growth medium without antibiotics.<list list-type="alpha-lower"><list-item><p>Grow overnight.</p></list-item><list-item><p>Confirm cells at 70–80% confluency by light microscopy at time of transfection.</p></list-item></list></p></list-item><list-item><p>Transfect 293T cells with pcDNA3, pcDNA3-IDH2<sup>WT</sup>, pcDNA3-IDH2<sup>R172K</sup> with Lipofectamine 2000 according to manufacturer instructions for a 6-well plate.<list list-type="alpha-lower"><list-item><p>As per manufacture’s instructions 1 µg plasmid DNA per well in a 6-well plate for 70–80% confluent 293T cells.</p></list-item><list-item><p>Transfect 1 well (or plate if reaction needs to be scaled up) for each construct<list list-type="roman-lower"><list-item><p>This will be one biological replicate</p></list-item></list></p></list-item></list></p></list-item><list-item><p>48 hr after transfection, remove medium from cells, wash with PBS, and lyse in 1 ml/well of mammalian protein extraction reagent containing protease inhibitor cocktail (aprotinin, AEBSF, leupeptin and pepstatin A, all at 1:1000) and phosphatase inhibitor cocktails (NaOV, Pepstatin A, Leupeptin, AEBSF, NaF, aprotinin) at 4°C or on ice.</p></list-item><list-item><p>Collect lysate and sonicate.<list list-type="alpha-lower"><list-item><p>Perform test for optimal conditions as follows.<list list-type="roman-lower"><list-item><p>Sonication for 5 min</p></list-item><list-item><p>Sonication for 10 min</p></list-item></list></p></list-item><list-item><p>Centrifuge lysate in refrigerated microcentrifuge at 14000x<italic>g</italic> at 4°C for 10 min.</p></list-item><list-item><p>Collect supernatants and measure the protein concentration of each using the DC Protein Assay Kit II according to the manufacturer’s instructions.</p></list-item><list-item><p>Will need &gt;50 µg total protein to proceed<list list-type="roman-lower"><list-item><p>If 50 µg total protein is not achieved the reaction will be scaled to a 25 cm plate. These conditions will be used for the subsequent replicates without any further optimization.</p></list-item><list-item><p>If further optimization is needed, the experiment will not proceed to step 7 until this is achieved.</p></list-item></list></p></list-item><list-item><p>Aliquot lysate protein for measuring IDH oxidative (Step 9) and reductive activity (step 10) and for examining expression of IDH2<sup>WT</sup>, IDH2<sup>R172K</sup> by western blot (step 11).</p></list-item></list></p></list-item><list-item><p>Measuring IDH oxidative activity:<list list-type="alpha-lower"><list-item><p>Mix 0.3 µg of each protein lysate with 200 µl of assay buffer solution in a 96-well plate. Each condition should be plated in triplicate.<list list-type="roman-lower"><list-item><p>Assay buffer solution: 100 mM Tris-HCl buffer (pH 7.5), 1.3 mM MnCl<sub>2</sub>, 0.33 mM EDTA, 0.1 mM ß-NADP<sup>+</sup>, 0.1 mM D-(+)-<italic>threo</italic>-isocitrate</p></list-item><list-item><p>Include buffer lacking lysate protein to determine background reading.</p></list-item></list></p></list-item><list-item><p>Put mixtures in spectrometer and measure absorbance at 340 nm every 20 s for 30 min.</p></list-item><list-item><p>Use absorbance readings at 5 min intervals for analysis.<list list-type="roman-lower"><list-item><p>An exploratory investigation of all data will be used in the analysis as well.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Measuring IDH reductive activity:<list list-type="alpha-lower"><list-item><p>Mix 3 µg of each protein lysate with 200 µl of assay buffer solution in a 96-well plate. Each condition should be plated in triplicate.<list list-type="roman-lower"><list-item><p>Assay buffer solution: 100 mM Tris-HCl buffer (ph 7.5), 1.3 mM MnCl<sub>2</sub>, 0.01 mM ß-NADPH, 0.5 mM α-ketoglutarate</p></list-item><list-item><p>Include buffer lacking lysate protein to determine background reading.</p></list-item></list></p></list-item><list-item><p>Put mixtures in spectrometer and measure absorbance at 340 nm every 20 min for 3 hr.</p></list-item></list></p></list-item><list-item><p>Western blot to confirm protein expression:<list list-type="alpha-lower"><list-item><p>Add sample buffer and boil lysates to prepare for loading.<list list-type="roman-lower"><list-item><p>Sample buffer: 0.5 mL 1 M TrisCl, pH 6.8, 1 mL glycerol, 0.5 mL ß-mercaptoethanol, 0.24 g SDS, 0.1 mL 1% bromophenol blue.</p></list-item><list-item><p>Add 30 µg of protein per well by diluting protein to same concentrations (based on protein quantification results) in 10 µL of lyse buffer and added 20 µL of sample buffer</p></list-item><list-item><p>Place at 65˚C for 15 min.</p></list-item></list></p></list-item><list-item><p>Separate 20–30 µg of protein per lane on an 8% SDS-PAGE gel with protein ladder.<list list-type="roman-lower"><list-item><p>Run through the stacker at 45 mAmp/gel, then increase to 300 V for 3 hr.</p></list-item></list></p></list-item><list-item><p>Transfer to nitrocellulose membrane.<list list-type="roman-lower"><list-item><p>Transfer at 100 A for 1 hr 40 min in 2.5 mM Tris, 19 mM glycine in 20% methanol.</p></list-item><list-item><p>Wash membrane in deionized water then wash in 1X TBST.</p></list-item><list-item><p>Confirm protein transfer with Ponceau stain.</p></list-item></list></p></list-item><list-item><p>Block membrane with 5% milk/0.2% azide in TBST for 30 min at room temperature.</p></list-item><list-item><p>Incubate with the following primary antibodies using the manufacturer’s recommended dilution. Following antibodies will be probed at one time<list list-type="roman-lower"><list-item><p>Mouse anti-IDH2; 37 kDa</p></list-item><list-item><p>Goat anti-IDH1; 47 kDa</p></list-item></list></p></list-item><list-item><p>Incubate with appropriate secondary antibodies using manufacture’s recommended dilutions<list list-type="roman-lower"><list-item><p>HRP-conjugated sheep anti-mouse</p></list-item><list-item><p>HRP-conjugated rabbit anti-goat<list list-type="order"><list-item><p>The anti-actin antibody is HRP conjugated and a secondary antibody incubation is not necessary.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Treat membranes with ECL reagent according to manufacturer’s recommendations and image.</p></list-item><list-item><p>Between antibody incubations, inactivate HRP activity by incubating with a final concentration of 1mM sodium azide in blocking buffer.<list list-type="roman-lower"><list-item><p>Shake at room temp for 1 hr.</p></list-item><list-item><p>Wash membrane 3 x 5 min in 1X TBST.</p></list-item><list-item><p>Incubate with ECL reagent as directed by the manufacturer and image at a time point of at least 5 min to confirm HRP inactivation</p></list-item><list-item><p>Save blank image</p></list-item></list></p></list-item><list-item><p>Incubate with Rabbit anti-actin-HRP; 45 kDa [additional] to evaluate loading control</p></list-item><list-item><p>Treat membranes with ECL reagent according to manufacturer’s recommendations and image.</p></list-item></list></p></list-item><list-item><p>Repeat steps 6–9 independently six additional times.</p></list-item></list></sec></sec><sec id="s2-1-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Sequencing reads and agarose gel images confirming vector identity and integrity<list list-type="bullet"><list-item><p>pcDNA3</p></list-item><list-item><p>pcDNA3-IDH2<sup>WT</sup></p></list-item><list-item><p>pcDNA3-IDH2<sup>R172K</sup></p></list-item></list></p></list-item><list-item><p>Raw data from plate reader for reduced NADP<sup>+</sup> and oxidated NADPH</p></list-item><list-item><p>Background subtracted readings</p></list-item><list-item><p>Full western images, including ladder<list list-type="bullet"><list-item><p>Ponceau stains confirming protein transfer</p></list-item><list-item><p>ECL negative control from step 9-hr</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-1-5"><title>Confirmatory analysis plan</title><p>Statistical Analysis of the Replication Data:</p><list list-type="bullet"><list-item><p>Note: At the time of analysis, we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed, we will perform the appropriate transformation to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non-parametric Wilcoxon-Mann-Whitney test.<list list-type="bullet"><list-item><p>For oxidative activity assays:<list list-type="bullet"><list-item><p>Bonferroni corrected ANOVA followed by two-tailed Bonferroni corrected planned contrasts:<list list-type="bullet"><list-item><p>Vector vs. IDH2<sup>WT</sup></p></list-item><list-item><p>Vector vs. IDH2<sup>R172K</sup></p></list-item></list></p></list-item></list></p></list-item><list-item><p>For reductive activity assays<list list-type="bullet"><list-item><p>Bonferroni corrected ANOVA followed by two-tailed Bonferroni corrected planned contrasts:<list list-type="bullet"><list-item><p>Vector vs. IDH2<sup>WT</sup></p></list-item><list-item><p>Vector vs. IDH2<sup>R172K</sup></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Western blot:<list list-type="bullet"><list-item><p>This is a quality control experiment and is not powered to detect a specific effect.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt:<list list-type="bullet"><list-item><p>This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></p></list-item></list></sec><sec id="s2-1-6"><title>Known differences from the original study</title><p>Although not performed by the original authors, actin was added as internal loading control for Western blots and will be added to the resulting data. Details of the Western blot protocol and possible stripping/sodium azide treatment were unspecified; information was added by the replicating lab. The details of the transfection specifics were unspecified and that information is provided by the replicating lab. Additionally, these experiments will be conducted in 6-well dishes, however, if total protein yield is not sufficient, the replicating lab will scale up to 25 cm dishes.</p></sec><sec id="s2-1-7"><title>Provisions for quality control</title><p>All data obtained from the experiment - raw data, data analysis, control data, and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<ext-link ext-link-type="uri" xlink:href="https://osf.io/8l4ea/">https://osf.io/8l4ea/</ext-link>).</p><list list-type="bullet"><list-item><p>STR profiling and mycoplasma testing results</p></list-item><list-item><p>Sequencing reads and agarose gel images confirming vector identity and integrity</p></list-item><list-item><p>Ponceau stains confirming protein transfer for Western Blot</p></list-item><list-item><p>Confirmation of HRP inactivation prior to proceeding with the following antibodies.</p></list-item></list></sec></sec><sec id="s2-2"><title>Protocol 2: Production of 2-HG from IDH2 WT and mutant transfected cells</title><p>In this protocol, the production of 2-HG from 293T cells transfected with vectors expressing IDH2<sup>WT</sup> or IDH2<sup>R172K</sup> is measured by gas chromatography-mass spectrometry (as seen in Figures 3A–C). The amount of 2-HG relative to glutamate is quantified, as seen in Figure 3D.</p><sec id="s2-2-1"><title>Sampling</title><list list-type="bullet"><list-item><p>Experiment will be performed with at least three biological replicates for a final power of at least 80%. The original data are qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.<list list-type="bullet"><list-item><p>See Power Calculations section for details.</p></list-item></list></p></list-item><list-item><p>Experiment has three conditions:<list list-type="bullet"><list-item><p>Condition 1:293T cells expressing IDH2<sup>WT</sup></p></list-item><list-item><p>Condition 2: 293T cells expressing IDH2<sup>R172K</sup></p></list-item><list-item><p>Condition 3: 293T cells expressing empty pCDNA3 vector</p></list-item></list></p></list-item><list-item><p>For each condition, lysates will be analyzed for 2-HG/glutamate levels</p></list-item></list></sec><sec id="s2-2-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>293T cells</td><td>Cells</td><td>ATCC</td><td>CRL-3216</td><td>Original source unspecified</td></tr><tr><td>Dulbecco’s modified <break/>Eagle’s medium (DMEM)</td><td>Media</td><td>Invitrogen</td><td>11965118</td><td>Original unspecified</td></tr><tr><td>Pen/Strep</td><td>Reagent</td><td>Fisher</td><td>15140-122</td><td>Original unspecified</td></tr><tr><td>FBS</td><td>Reagent</td><td>Hyclone</td><td>SH30071.03</td><td>Replaces FBS from CellGro</td></tr><tr><td>pcDNA-IDH2<sup>WT</sup></td><td>Plasmid</td><td colspan="3">Generated in <break/>Protocol 1</td></tr><tr><td>pcDNA-IDH2<sup>R172K</sup></td><td>Plasmid</td><td colspan="3">Generated in <break/>Protocol 1</td></tr><tr><td>Lipofectamine 2000</td><td>Reagent</td><td>Invitrogen</td><td>11668027</td><td/></tr><tr><td>Methanol</td><td>Reagent</td><td>Fisher</td><td>A452SK-4</td><td>Original unspecified</td></tr><tr><td>Refrigerated centrifuge</td><td>Equipment</td><td>Labnet International, Inc</td><td>PrismR</td><td>Original unspecified</td></tr><tr><td>Nitrogen gas</td><td>Reagent</td><td colspan="2">Generated in lab</td><td>Original unspecified</td></tr><tr><td>AG-1 X8 100-200 <break/>anion exchange column</td><td>Reagent</td><td>Bio-Rad</td><td>731-6211</td><td>Poly-Prep Columns, AG 1-X8, chloride form</td></tr><tr><td>HCl</td><td>Reagent</td><td>Fisher</td><td>SA56-1</td><td>Original unspecified</td></tr><tr><td>N-methyl-N-tert- <break/>butyldimethylsily <break/>trifluoroacetamide (MTBSTFA; Regis)</td><td>Reagent</td><td>Regis</td><td>1-270243-200</td><td/></tr><tr><td>Gas Chromatograph with <break/>an HP-5MS capillary column <break/>and Mass selective detector</td><td>Equipment</td><td colspan="2">Agilent 7890A <break/>with 7693 Autosampler</td><td/></tr><tr><td>Cold trap concentrator</td><td>Equiptment</td><td>Labconco Centrivap</td><td/><td/></tr><tr><td>R(-)-2-HG</td><td>Reagent</td><td>Sigma-Aldrich</td><td>H8378-100MG</td><td>Original unspecified</td></tr></tbody></table></table-wrap></sec><sec id="s2-2-3"><title>Procedure</title><sec id="s16"><title>Notes</title><list list-type="bullet"><list-item><p>293T cells grown in DMEM supplemented with 10% FBS at 37°C in 5% CO<sub>2</sub>.</p></list-item><list-item><p>All cells will be sent for STR profiling and mycoplasma testing</p></list-item></list><list list-type="order"><list-item><p>Seed 0.25–1 x 10<sup>6</sup> 293T cells per well of a 6-well plate in growth medium without antibiotics.<list list-type="alpha-lower"><list-item><p>Grow overnight.</p></list-item><list-item><p>Confirm cells at 70–80% confluence by light microscopy at time of transfection.</p></list-item></list></p></list-item><list-item><p>Transfect 293T cells with pCDNA3, pCDNA3-IDH2<sup>WT</sup>, or pCDNA3-IDH2<sup>R172K</sup> with Lipofectamine 2000 according to manufacturer instructions.<list list-type="alpha-lower"><list-item><p>Transfect 1 µg of plasmid DNA per well in 6-well plate at 70–80% confluence.</p></list-item><list-item><p>Generate duplicate plates for each transfection:<list list-type="roman-lower"><list-item><p>Harvest one plate at 24 hr.</p></list-item><list-item><p>Harvest one plate at 48 hr.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>24 hr later, replace with fresh media with 1x pen/strep</p></list-item><list-item><p>24 or 48 hr later, gently remove medium from proliferating cells.<list list-type="alpha-lower"><list-item><p>Note: from this point on this protocol contains information as described in (<xref ref-type="bibr" rid="bib1">Bennett et al., 2008</xref>).</p></list-item></list></p></list-item><list-item><p>Rapidly quench cells with 1–2 ml per well of -80°C methanol.<list list-type="alpha-lower"><list-item><p>Chill cells to -80°C and incubate at -80°C for 15 min.</p></list-item></list></p></list-item><list-item><p>Scrape cells off the dish and transfer the cell suspension to a 15 ml conical tube.<list list-type="alpha-lower"><list-item><p>Centrifuge for 5 min at 2000x<italic>g</italic> at 4°C to pellet cellular debris.</p></list-item><list-item><p>Transfer supernatant to a fresh 15 ml tube.</p></list-item></list></p></list-item><list-item><p>Resuspend the pellet in 500 µl of -80°C 80% methanol in water by vortexing.<list list-type="alpha-lower"><list-item><p>Incubate at 4°C for 15 min.</p></list-item><list-item><p>Centrifuge for 5 min at 2000x<italic>g</italic> at 4°C.</p></list-item><list-item><p>Combine supernatant with supernatant from Step 6b.</p></list-item><list-item><p>Repeat step 7 for a third round of extraction and combine all supernatants.</p></list-item></list></p></list-item><list-item><p>Evaporate to dryness using a cold trap concentrator.</p></list-item><list-item><p>Elute through an AG-1 X8 100–200 anion exchange resin according to the manufacturer’s instructions.<list list-type="alpha-lower"><list-item><p>Wash with five column volumes of wash buffer.</p></list-item><list-item><p>Elute in 3N HCl.</p></list-item></list></p></list-item><list-item><p>Evaporate to dryness using cold trap concentrator</p></list-item><list-item><p>Redissolve sample in MSTFA + FAME.<list list-type="alpha-lower"><list-item><p>Prepare 40 mg/mL Methoxyamine hydrochloride (MeOX) solution in pyridine.<list list-type="roman-lower"><list-item><p>Weigh out methoxyamine hydrochloride in 1.5 ml Eppendorf tube on balance and add appropriate amount of pyridine.</p></list-item></list></p></list-item><list-item><p>Vortex MeOX solution and sonicate at 60°C for 15 min to dissolve.</p></list-item><list-item><p>Add 10 µl of 40 mg/ml MeOX solution to each dried sample.</p></list-item><list-item><p>Shake at maximum speed at 60˚C for 1 hr.</p></list-item><list-item><p>To 1 ml of MSTFA, add 10 µl of FAME marker.<list list-type="roman-lower"><list-item><p>Vortex for 10 s.</p></list-item></list></p></list-item><list-item><p>Add 91 µl of MSTFA + FAME mixture to each sample and standard. Cap immediately.<list list-type="roman-lower"><list-item><p>Shake at maximum speed at 37°C.</p></list-item></list></p></list-item><list-item><p>Transfer contents to glass vials with micro-inserts and cap immediately.<list list-type="roman-lower"><list-item><p>Submit to GCTOF MS analysis.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Inject samples into GC-MS.<list list-type="alpha-lower"><list-item><p>Operate the detector in spitless mode using electron impact ionization.<list list-type="roman-lower"><list-item><p>Ionizing voltage: -70 eV</p></list-item><list-item><p>Electron multiplier: 1060 V</p></list-item></list></p></list-item><list-item><p>GC temperature ramp:<list list-type="roman-lower"><list-item><p>Hold at 100°C for 3 min.</p></list-item><list-item><p>Ramp to 230°C at 4°C/min.</p></list-item><list-item><p>Hold for 4 min.</p></list-item><list-item><p>Ramp to 300°C.</p></list-item><list-item><p>Hold for 5 min.</p></list-item></list></p></list-item><list-item><p>Record mass range of 50–500 amu and record 2.71 scans/s.</p></list-item></list></p></list-item><list-item><p>Repeat steps 1–12 independently three additional times.</p></list-item></list></sec></sec><sec id="s2-2-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>24 hr samples:<list list-type="bullet"><list-item><p>GC traces for all samples run<list list-type="bullet"><list-item><p>Close-up of the time range showing metabolite abundance for aspartate, glutamate, and 2-HG for cells transfected with IDH2<sup>WT</sup> (Figure 3A) and cells transfected with IDH2<sup>R172K</sup> (Figure 3B).<list list-type="bullet"><list-item><p>Mass spectrum confirmation of metabolite identity as 2-HG.</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>48 hr run<list list-type="bullet"><list-item><p>GC traces for all samples run<list list-type="simple"><list-item><p>Close-up of the time range showing metabolite abundance for aspartate, glutamate, and 2-HG for cells transfected with IDH2<sup>WT</sup> (Figure 3A) and cells transfected with IDH2<sup>R172K</sup> (Figure 3B).</p></list-item></list></p></list-item><list-item><p>Quantification of the relative intensity of the 2-HG signal to the glutamate signal, graphed as seen in Figure 3D.</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-2-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data:</p></list-item><list-item><p>Note: At the time of analysis, we will perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the data. We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed, we will perform the appropriate transformation to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non-parametric test.<list list-type="bullet"><list-item><p>Two-way ANOVA performed on 2-HG/glutamate ratios followed by Fisher’s LSD for the following comparisons:<list list-type="simple"><list-item><p><list list-type="bullet"><list-item><p>Vector vs. IDH2<sup>WT</sup></p></list-item><list-item><p>IDH2<sup>WT</sup> vs. IDH2<sup>R172K</sup></p></list-item></list></p></list-item><list-item><p>o Analyses will be performed on both 24 and 48 hr runs.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt:<list list-type="bullet"><list-item><p>The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the graph, as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></sec><sec id="s2-2-6"><title>Known differences from the original study</title><list list-type="bullet"><list-item><p>The GC-MS sample preparation protocol was modified by the replicating lab including a shaking incubation step at 11f. However, this protocol was taken from Bennett et al. which the authors reference in the original manuscript.</p></list-item></list></sec><sec id="s2-2-7"><title>Provisions for quality control</title><p>All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<ext-link ext-link-type="uri" xlink:href="https://osf.io/8l4ea/">https://osf.io/8l4ea/</ext-link>).</p><list list-type="bullet"><list-item><p>STR profiling and mycoplasma testing results.</p></list-item><list-item><p>Mass spectrum of the metabolite peak for derivatized 2HG to confirm identity.</p></list-item></list></sec></sec><sec id="s2-3"><title>Protocol 3: Assessing the correlation of IDH status with 2-HG levels in samples from patients with AML</title><p>In this protocol, samples from patients with acute myeloid leukemia (AML) are examined for their IDH mutational status and their level of 2-HG, as seen in Figure 5.</p><sec id="s2-3-1"><title>Sampling</title><list list-type="bullet"><list-item><p>This experiment will use four samples per group for a final power of at least 80%.<list list-type="bullet"><list-item><p>See Power Calculations section for details.</p></list-item></list></p></list-item><list-item><p>This experiment has three genetically distinct groups:<list list-type="bullet"><list-item><p>AML patients with no <italic>IDH</italic> mutations</p></list-item><list-item><p>AML patients with mutant <italic>IDH1</italic></p></list-item><list-item><p>AML patients with mutant <italic>IDH2,</italic> including both R172K and R140Q mutants</p></list-item></list></p></list-item><list-item><p>All samples will come from Roswell Park Cancer Institute and are ficoll separated in media with 10% DMSO and prescreened for <italic>IDH</italic> genotypic status.</p></list-item><list-item><p>Each patient sample will be assessed for their ratio of 2-HG/glutamate.</p></list-item></list></sec><sec id="s2-3-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>Samples of peripheral blood, bone marrow, <break/>or pheresis from patients <break/>with karyotypically normal AML</td><td>Patient sample</td><td>NA</td><td>NA</td><td>Banked RPCI samples</td></tr><tr><td>DMSO</td><td>Reagent</td><td>Fisher</td><td>BP231-1</td><td>Original Unspecified</td></tr><tr><td>Methanol</td><td>Reagent</td><td>Fisher</td><td>A452SK-4</td><td>Original unspecified</td></tr><tr><td>Refrigerated centrifuge</td><td>Equipment</td><td>Labnet International, Inc</td><td>PrismR</td><td>Original unspecified</td></tr><tr><td>AG-1 X8 100-200 <break/>anion exchange column</td><td>Reagent</td><td>Bio-Rad</td><td>731-6211</td><td>Poly-Prep Columns, AG 1-X8, chloride form</td></tr><tr><td>HCl</td><td>Reagent</td><td>Fisher</td><td>SA56-1</td><td>Original unspecified</td></tr><tr><td>N-methyl-N-tert- <break/>butyldimethylsily <break/>trifluoroacetamide (MTBSTFA; Regis)</td><td>Reagent</td><td>Regis</td><td>1-270243-200</td><td/></tr><tr><td>Gas Chromatograph with an <break/>HP-5MS capillary column and Mass selective detector</td><td>Equipment</td><td>Agilent 7890A with <break/>7693 Autosampler</td><td/><td/></tr><tr><td>Cold trap concentrator</td><td>Equiptment</td><td>Labconco Centrivap</td><td/><td/></tr></tbody></table></table-wrap></sec><sec id="s2-3-3"><title>Procedure</title><list list-type="order"><list-item><p>GC-MS analysis of 2-HG levels.<list list-type="alpha-lower"><list-item><p>If using frozen cells, warm cells to 37˚C in a 37˚C water bath for 10 min</p></list-item><list-item><p>Centrifuge cells for 5 min at 1000x<italic>g</italic> to form a pellet<list list-type="roman-lower"><list-item><p>If necessary, transfer cells to a conical or microcentrifuge tube</p></list-item></list></p></list-item><list-item><p>Gently remove freezing medium from MNCs</p></list-item><list-item><p>Proceed with metabolite extraction and GC-MS analysis as detailed in protocol 2 Steps 5 through 12.</p></list-item><list-item><p>For each sample, divide the GC signal intensity of their 2-HG peak by the signal intensity of their glutamate peak and graph.</p></list-item></list></p></list-item></list></sec><sec id="s2-3-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Tabulated patient data (age, sex, <italic>IDH</italic> mutation status, 2-HG/glutamate ratio) (as seen in Table 1)</p></list-item><list-item><p>GC traces for all samples</p></list-item><list-item><p>Graph of 2-HG/glutamate ratio for samples by mutational status, as seen in Figure 5C.</p></list-item></list></p></list-item></list></sec><sec id="s2-3-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data:</p></list-item><list-item><p>Note: The authors report WT IDH ratios were less than 1% which we are using as the constant for the comparisons below.<list list-type="bullet"><list-item><p>Bonferroni Correct one-sample t-test for 3 comparisons (alpha corrected for 2 test groups = 0.025)<list list-type="bullet"><list-item><p>Constant vs. <italic>IDH1<sup>mutant</sup></italic></p></list-item><list-item><p>Constant vs. <italic>IDH2<sup>mutant</sup></italic></p></list-item><list-item><p>Constant vs <italic>IDH1/2<sup>mutants</sup></italic></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt:<list list-type="bullet"><list-item><p>This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></p></list-item></list></sec><sec id="s2-3-6"><title>Known differences from the original study</title><list list-type="bullet"><list-item><p>The GC-MS sample preparation protocol was modified by the replicating lab including a shaking incubation step at 11f, protocol 2. However, this protocol was taken from Bennett et al. which the authors reference in the original manuscript.</p></list-item></list></sec><sec id="s2-3-7"><title>Provisions for quality control</title><p>All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<ext-link ext-link-type="uri" xlink:href="https://osf.io/8l4ea/">https://osf.io/8l4ea/</ext-link>). This includes confirmation of the GCMS peaks and elution times as well as MS QC data.</p></sec></sec><sec id="s2-4"><title>Power calculations</title><p>For details of power calculations, see spreadsheet and additional files at <ext-link ext-link-type="uri" xlink:href="https://osf.io/9jkpg/">https://osf.io/9jkpg/</ext-link></p><sec id="s2-4-1"><title>Protocol 1</title><p>Summary of original data estimated from graph reported in Figure 2A:</p><list list-type="bullet"><list-item><p>SD was calculated using formula SD = SEM*(SQRT n=3).</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Sample</th><th>Time</th><th>Mean</th><th>SEM</th><th>SD</th></tr></thead><tbody><tr><td rowspan="7">IDH2<sup>WT</sup></td><td>0</td><td>0</td><td>0.0820</td><td>0.1421</td></tr><tr><td>5</td><td>0.225</td><td>0.0820</td><td>0.1421</td></tr><tr><td>10</td><td>0.45</td><td>0.1025</td><td>0.1776</td></tr><tr><td>15</td><td>0.679</td><td>0.1538</td><td>0.2664</td></tr><tr><td>20</td><td>0.917</td><td>0.1974</td><td>0.3419</td></tr><tr><td>25</td><td>1.129</td><td>0.2512</td><td>0.4352</td></tr><tr><td>30</td><td>1.342</td><td>0.3</td><td>0.5196</td></tr><tr><td rowspan="7">IDH2<sup>R172K</sup></td><td>0</td><td>0</td><td>0.0820</td><td>0.1421</td></tr><tr><td>5</td><td>0.038</td><td>0.0820</td><td>0.1421</td></tr><tr><td>10</td><td>0.062</td><td>0.0820</td><td>0.1421</td></tr><tr><td>15</td><td>0.062</td><td>0.0820</td><td>0.1421</td></tr><tr><td>20</td><td>0.062</td><td>0.0820</td><td>0.1421</td></tr><tr><td>25</td><td>0.1</td><td>0.0820</td><td>0.1421</td></tr><tr><td>30</td><td>0.096</td><td>0.0820</td><td>0.1421</td></tr><tr><td rowspan="7">Vector</td><td>0</td><td>0</td><td>0.0564</td><td>0.0977</td></tr><tr><td>5</td><td>0.021</td><td>0.0564</td><td>0.0977</td></tr><tr><td>10</td><td>0.021</td><td>0.0564</td><td>0.0977</td></tr><tr><td>15</td><td>0.017</td><td>0.0564</td><td>0.0977</td></tr><tr><td>20</td><td>0.017</td><td>0.0564</td><td>0.0977</td></tr><tr><td>25</td><td>0.033</td><td>0.0564</td><td>0.0977</td></tr><tr><td>30</td><td>0.021</td><td>0.0564</td><td>0.0977</td></tr></tbody></table></table-wrap><p>Linear regression to determine slopes from estimate values.</p><p>Calculations performed with R software (version 3.2.2) (<xref ref-type="bibr" rid="bib13">R Core Team, 2015</xref>)</p><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Sample</th><th>Mean slope</th><th>SD</th><th>N</th></tr></thead><tbody><tr><td>IDH2<sup>WT</sup></td><td>0.01</td><td>0.090</td><td>3</td></tr><tr><td>IDH2<sup>R172K</sup></td><td>0.06</td><td>0.140</td><td>3</td></tr><tr><td>Vector</td><td>0.67</td><td>0.280</td><td>3</td></tr></tbody></table></table-wrap><p>Summary of original data estimated from graph reported in Figure 2B:</p><list list-type="bullet"><list-item><p>SD was calculated using formula SD = SEM*(SQRT(n)), where n = 3.</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Sample</th><th>Time</th><th>Original_Value_Mean</th><th>SEM</th><th>SD</th></tr></thead><tbody><tr><td rowspan="9">IDH2<sup>WT</sup></td><td>0</td><td>0</td><td>0.0039</td><td>0.0067</td></tr><tr><td>17</td><td>-0.003</td><td>0.0060</td><td>0.0105</td></tr><tr><td>33</td><td>-0.004</td><td>0.0073</td><td>0.0126</td></tr><tr><td>50</td><td>-0.005</td><td>0.0102</td><td>0.0177</td></tr><tr><td>71</td><td>-0.006</td><td>0.0104</td><td>0.0181</td></tr><tr><td>90</td><td>-0.008</td><td>0.0114</td><td>0.0198</td></tr><tr><td>112</td><td>-0.009</td><td>0.0117</td><td>0.0202</td></tr><tr><td>131</td><td>-0.01</td><td>0.0075</td><td>0.0130</td></tr><tr><td>171</td><td>-0.014</td><td>0.0121</td><td>0.0211</td></tr><tr><td rowspan="9">IDH2<sup>R172K</sup></td><td>0</td><td>0</td><td>0.0039</td><td>0.0067</td></tr><tr><td>17</td><td>-0.006</td><td>0.0039</td><td>0.0067</td></tr><tr><td>33</td><td>-0.009</td><td>0.0065</td><td>0.0114</td></tr><tr><td>50</td><td>-0.016</td><td>0.0085</td><td>0.0147</td></tr><tr><td>71</td><td>-0.024</td><td>0.0080</td><td>0.0139</td></tr><tr><td>90</td><td>-0.028</td><td>0.0087</td><td>0.0152</td></tr><tr><td>112</td><td>-0.036</td><td>0.0095</td><td>0.0164</td></tr><tr><td>131</td><td>-0.043</td><td>0.0104</td><td>0.0181</td></tr><tr><td>171</td><td>-0.055</td><td>0.0095</td><td>0.0164</td></tr><tr><td rowspan="9">Vector</td><td>0</td><td>0</td><td>0.0026</td><td>0.0046</td></tr><tr><td>17</td><td>0.001</td><td>0.0026</td><td>0.0046</td></tr><tr><td>33</td><td>0</td><td>0.0026</td><td>0.0046</td></tr><tr><td>50</td><td>0</td><td>0.0026</td><td>0.0046</td></tr><tr><td>71</td><td>0</td><td>0.0026</td><td>0.0046</td></tr><tr><td>90</td><td>0</td><td>0.0026</td><td>0.0046</td></tr><tr><td>112</td><td>-0.002</td><td>0.0026</td><td>0.0046</td></tr><tr><td>131</td><td>-0.002</td><td>0.0026</td><td>0.0046</td></tr><tr><td>171</td><td>-0.003</td><td>0.0026</td><td>0.0046</td></tr></tbody></table></table-wrap><p>Linear regression to determine slopes from estimates values.</p><p>Calculations performed with R software (version 3.2.2) (<xref ref-type="bibr" rid="bib13">R Core Team, 2015</xref>)</p><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Sample</th><th>Mean slope</th><th>SD</th><th>N</th></tr></thead><tbody><tr><td>IDH2<sup>WT</sup></td><td>-0.0006</td><td>0.005</td><td>3</td></tr><tr><td>IDH2<sup>R172K</sup></td><td>-0.0241</td><td>0.013</td><td>3</td></tr><tr><td>Vector</td><td>-0.0065</td><td>0.016</td><td>3</td></tr></tbody></table></table-wrap></sec><sec id="s2-4-2"><title>Test family</title><list list-type="bullet"><list-item><p>One-way ANOVA: Fixed effects, omnibus, one-way: Bonferroni correction: alpha error = 0.025.</p></list-item></list></sec><sec id="s2-4-3"><title>Power calculations</title><list list-type="bullet"><list-item><p>Power calculations were performed using G*Power, version 3.1.7 (<xref ref-type="bibr" rid="bib4">Faul et al., 2007</xref>).</p></list-item><list-item><p>ANOVA F test statistic and partial η<sup>2</sup>performed with R software, version 3.2.2 (<xref ref-type="bibr" rid="bib13">R Core Team, 2015</xref>).</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>F test statistic</th><th>Partial η<sup>2</sup></th><th>Effect size <italic>f</italic></th><th>A priori power</th><th>Total sample size</th></tr></thead><tbody><tr><td>Slopes of NADPH <break/>production from <break/>IDH2<sup>WT</sup>, IDH2<sup>R172</sup>, <break/>or Vector (Figure 2A)</td><td>F(2,6) = 10.8</td><td>0.7826</td><td>1.897636</td><td>99.99%<sup>1</sup></td><td>21<sup>1</sup> <break/>(3 groups)</td></tr><tr><td>Slopes of NADP<sup>+</sup> <break/>production from <break/>IDH2<sup>WT</sup>, IDH2<sup>R172</sup>, <break/>or Vector (Figure 2B)</td><td>F(2,6) = 3.02</td><td>0.5023</td><td>1.0048</td><td>94.13%<sup>1</sup></td><td>21<sup>1</sup> (3 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p><sup>1</sup> 7 samples per group will be used based on the planned comparisons making the power at least 80%.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-4-4"><title>Test family</title><list list-type="bullet"><list-item><p>2 tailed <italic>t</italic> test, Wilcoxon-Mann-Whitney test, Bonferroni’s correction: alpha error = 0.0125</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib4">Faul et al., 2007</xref>).</p><sec id="s34"><title>Figure 2A (NADPH production) values</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>Vector</td><td>IDH2<sup>WT</sup></td><td>3.05134</td><td>98.8%<sup>1</sup></td><td>7<sup>1</sup></td><td>7<sup>1</sup></td></tr><tr><td>Vector</td><td>IDH2<sup>R172K</sup></td><td>2.12463<sup>2</sup></td><td>80.0%<sup>2</sup></td><td>7</td><td>7</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><p><sup>1</sup> 7 samples per group will be used based on the Vector vs IDH2<sup>R172K</sup> NADP<sup>+</sup> planned comparison making the power 98.8%.</p></fn><fn id="tblfn3"><p><sup>2</sup> A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with 80% power and the indicated sample size. The original effect size reported was 0.49386.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s35"><title>Figure 2B (NADP<sup>+</sup> production) values</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>Vector</td><td>IDH2<sup>WT</sup></td><td>2.12463<sup>1</sup></td><td>80.0%<sup>1</sup></td><td>7</td><td>7</td></tr><tr><td>Vector</td><td>IDH2<sup>R172K</sup></td><td>2.21471</td><td>89.3%</td><td>7</td><td>7</td></tr></tbody></table><table-wrap-foot><fn id="tblfn4"><p><sup>1</sup> A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with 80% power and the indicated sample size. The original effect size reported was 0.47369.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s2-4-5"><title>Test family</title><list list-type="bullet"><list-item><p>Due to the large variance, these parametric tests are only used for comparison purposes. To ensure an adequate sample size is used, the number is based on the non-parametric tests listed above.</p></list-item><list-item><p>2 tailed <italic>t</italic> test, difference between two independent means, Bonferroni’s correction: alpha error = 0.0125</p></list-item></list><p>Power Calculations performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib4">Faul et al., 2007</xref>).</p><sec id="s37"><title>Figure 2A (NADPH production) values</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>Vector</td><td>IDH2<sup>WT</sup></td><td>3.05134</td><td>99.2%<sup>1</sup></td><td>7<sup>1</sup></td><td>7<sup>1</sup></td></tr><tr><td>Vector</td><td>IDH2<sup>R172K</sup></td><td>2.03<sup>2</sup></td><td>80.0%<sup>2</sup></td><td>7</td><td>7</td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p><sup>1</sup>Seven samples per group will be used based on the Vector vs IDH2<sup>R172K</sup> NADP<sup>+</sup> planned comparison making the power 98.8%.</p></fn><fn id="tblfn6"><p><sup>2</sup> A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with 80% power and the indicated sample size. The original effect size reported was 0.33972.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s38"><title>Figure 2B (NADP<sup>+</sup> production) values</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1</th><th>Group 2</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group 1 sample size</th><th>Group 2 sample size</th></tr></thead><tbody><tr><td>Vector</td><td>IDH2<sup>WT</sup></td><td>2.05829<sup>1</sup></td><td>80.0%<sup>1</sup></td><td>7</td><td>7</td></tr><tr><td>Vector</td><td>IDH2<sup>R172K</sup></td><td>2.03</td><td>90.4%</td><td>7</td><td>7</td></tr></tbody></table><table-wrap-foot><fn id="tblfn7"><p><sup>1</sup> A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with 80% power and the indicated sample size. The original effect size reported was 0.51213.</p></fn></table-wrap-foot></table-wrap></sec></sec></sec><sec id="s2-5"><title>Protocol 2: Figure 3D</title><p>Summary of original data</p><list list-type="bullet"><list-item><p>Note: data estimated from published graphs</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Sample</th><th>Mean intracellular 2-HG/glutamate</th><th>Assumed N</th></tr></thead><tbody><tr><td>Vector</td><td>0.0105</td><td>3</td></tr><tr><td>IDH2<sup>WT</sup></td><td>0.0102</td><td>3</td></tr><tr><td>IDH2<sup>R172K</sup></td><td>1.2</td><td>3</td></tr></tbody></table></table-wrap><sec id="s2-5-1"><title>Test family</title><list list-type="bullet"><list-item><p>One way ANOVA followed by Bonferroni corrected planed comparisons:<list list-type="bullet"><list-item><p>Power calculations:<list list-type="bullet"><list-item><p>Vector vs. IDH2<sup>R172K</sup></p></list-item><list-item><p>IDH2<sup>WT</sup> vs. IDH2<sup>R172K</sup></p></list-item></list></p></list-item><list-item><p>Sensitivity Calculations<list list-type="bullet"><list-item><p>Vector vs. IDH2<sup>WT</sup></p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-5-2"><title>Power calculations</title><list list-type="bullet"><list-item><p>Power calculations were performed using GraphPad PRISM v6 and G*Power (version 3.1.7) (<xref ref-type="bibr" rid="bib4">Faul et al., 2007</xref>)</p></list-item><list-item><p>Because the data did not display variance, we have performed power calculations with a range of variances and an assumed N of 3 per group.</p></list-item><list-item><p>2% variance</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">ANOVA; α=0.05</th></tr></thead><tbody><tr><td>F(2,6)</td><td>Partial eta2</td><td>Effect size f</td><td>Power</td><td>Total N</td></tr><tr><td>7370</td><td>0.999593</td><td>49.55807</td><td>&gt;99.99%</td><td>6*</td></tr><tr><td colspan="5">Power calculations; α=0.05</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size d</td><td>Power</td><td>N/group</td></tr><tr><td>Vector</td><td>IDH2<sup>WT</sup></td><td>70.10710478</td><td>&gt;99.99%</td><td>2*</td></tr><tr><td>IDH2<sup>WT</sup></td><td>IDH2<sup>R172K</sup></td><td>70.08927663</td><td>&gt;99.99%</td><td>2*</td></tr><tr><td colspan="5">Sensitivity Calculations; α=0.05, powered to 80%</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size d</td><td>Detectable d</td><td>N/group</td></tr><tr><td>Vector</td><td>IDH2<sup>R172K</sup></td><td>1.449123183</td><td>0.2774844</td><td>3</td></tr></tbody></table><table-wrap-foot><fn id="tblfn8"><p>*With a minimum of 3 per group (9 total), achieved power is &gt;99.99%.</p></fn></table-wrap-foot></table-wrap><list list-type="bullet"><list-item><p>15% variance</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">ANOVA; α=0.05</th></tr></thead><tbody><tr><td>F(2,6)</td><td>Partial eta2</td><td>Effect size f</td><td>Power</td><td>Total N</td></tr><tr><td>131</td><td>0.977612</td><td>6.608085</td><td>99.99%</td><td>6*</td></tr><tr><td colspan="5">Power calculations; α=0.05</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size d</td><td>Power</td><td>N/group</td></tr><tr><td>Vector</td><td>IDH2<sup>WT</sup></td><td>9.347613971</td><td>98.65%</td><td>2*</td></tr><tr><td>IDH2<sup>WT</sup></td><td>IDH2<sup>R172K</sup></td><td>9.345236884</td><td>98.65%</td><td>2*</td></tr><tr><td colspan="5">Sensitivity Calculations; α=0.05, powered to 80%</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size d</td><td>Detectable d</td><td>N/group</td></tr><tr><td>Vector</td><td>IDH2<sup>R172K</sup></td><td>0.193216424</td><td>0.0539826</td><td>3</td></tr></tbody></table><table-wrap-foot><fn id="tblfn9"><p>*With a minimum of 3 per group (9 total), achieved power is &gt;99.99%.</p></fn></table-wrap-foot></table-wrap><list list-type="bullet"><list-item><p>28% variance</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">ANOVA; α=0.05</th></tr></thead><tbody><tr><td>F(2,6)</td><td>Partial eta2</td><td>Effect size f</td><td>Power</td><td>Total N</td></tr><tr><td>37.60</td><td>0.926108</td><td>3.540235</td><td>98.61%</td><td>6*</td></tr><tr><td colspan="5">Power calculations; α=0.05</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size d</td><td>Power</td><td>N/group</td></tr><tr><td>Vector</td><td>IDH2<sup>WT</sup></td><td>5.007650342</td><td>99.28%</td><td>3</td></tr><tr><td>IDH2<sup>WT</sup></td><td>IDH2<sup>R172K</sup></td><td>5.006376902</td><td>99.28%</td><td>3</td></tr><tr><td colspan="5">Sensitivity Calculations; α=0.05, powered to 80%</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size d</td><td>Detectable d</td><td>N/group</td></tr><tr><td>Vector</td><td>IDH2<sup>R172K</sup></td><td>0.103508799</td><td>0.0511419</td><td>3</td></tr></tbody></table><table-wrap-foot><fn id="tblfn10"><p>*With a minimum of 3 per group (9 total), achieved power is 99.99%.</p></fn></table-wrap-foot></table-wrap><list list-type="bullet"><list-item><p>40% variance</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">ANOVA; α=0.05</th></tr></thead><tbody><tr><td>F(2,6)</td><td>Partial eta2</td><td>Effect size f</td><td>Power</td><td>Total N</td></tr><tr><td>18.43</td><td>0.860009</td><td>2.478571</td><td>85.73%</td><td>6*</td></tr><tr><td colspan="5">Power calculations; α=0.05</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size d</td><td>Power</td><td>N/group</td></tr><tr><td>Vector</td><td>IDH2<sup>WT</sup></td><td>3.505355239</td><td>88.73%</td><td>3</td></tr><tr><td>IDH2<sup>WT</sup></td><td>IDH2R172K</td><td>4.205285771</td><td>96.37%</td><td>3</td></tr><tr><td colspan="5">Sensitivity Calculations; α=0.05, powered to 80%</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size d</td><td>Detectable d</td><td>N/group</td></tr><tr><td>Vector</td><td>IDH2<sup>R172K</sup></td><td>0.072456159</td><td>0.0505594</td><td>3</td></tr></tbody></table><table-wrap-foot><fn id="tblfn11"><p>*With a minimum of 3 per group (9 total), achieved power is 99.92%.</p></fn></table-wrap-foot></table-wrap><list list-type="bullet"><list-item><p>In order to produce quantitative replication data, we will run the experiment three times. We will determine the standard deviation across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p></list-item><list-item><p>Note: Simulation analysis was also conducted using randomly generated values based on the SD and variance desired. These data are comparable to what is seen above when using a parametric model approach. Also there may be a need to appropriately transform these data based on the scale of Figure 3D, and we have assumed that this is one representative sample and not averages of all the data showing no variance. This simulation will be loaded to the OSF (<ext-link ext-link-type="uri" xlink:href="https://osf.io/8l4ea/">https://osf.io/8l4ea/</ext-link>).</p></list-item></list></sec></sec><sec id="s2-6"><title>Protocol 3: Figure 5C</title><sec id="s2-6-1"><title>Summary of original data</title><list list-type="bullet"><list-item><p>Note: data estimated from published graphs and log transformed. Data includes IDH<sup>WT</sup> (no mutations in <italic>IDH1</italic> or <italic>IDH2</italic>), IDH1<sup>R132C/G</sup>, IDH2<sup>Mutant</sup> (IDH2<sup>R172K</sup> and IDH2<sup>R140Q</sup>)</p></list-item></list><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Sample</th><th>2HG/glutamate</th><th>log(2HG/glut)</th></tr></thead><tbody><tr><td>IDH<sup>WT</sup>(Constant)</td><td>0.01</td><td>-4.605</td></tr><tr><td>IDH1<sup>Mutant</sup></td><td>0.600</td><td>-0.511</td></tr><tr><td>IDH1<sup>Mutant</sup></td><td>1.200</td><td>0.182</td></tr><tr><td>IDH1<sup>Mutant</sup></td><td>1.600</td><td>0.470</td></tr><tr><td>IDH1<sup>Mutant</sup></td><td>1.800</td><td>0.588</td></tr><tr><td>IDH1<sup>Mutant</sup></td><td>3.000</td><td>1.099</td></tr><tr><td>IDH1<sup>Mutant</sup></td><td>0.600</td><td>-0.511</td></tr><tr><td>IDH2<sup>Mutant</sup></td><td>0.140</td><td>-1.966</td></tr><tr><td>IDH2<sup>Mutant</sup></td><td>0.160</td><td>-1.832</td></tr><tr><td>IDH2<sup>Mutant</sup></td><td>0.290</td><td>-1.237</td></tr><tr><td>IDH2<sup>Mutant</sup></td><td>0.300</td><td>-1.204</td></tr><tr><td>IDH2<sup>Mutant</sup></td><td>0.310</td><td>-1.171</td></tr><tr><td>IDH2<sup>Mutant</sup></td><td>0.470</td><td>-0.755</td></tr><tr><td>IDH2<sup>Mutant</sup></td><td>0.590</td><td>-0.528</td></tr><tr><td>IDH2<sup>Mutant</sup></td><td>0.310</td><td>-1.171</td></tr></tbody></table></table-wrap></sec><sec id="s2-6-2"><title>Test family</title><list list-type="bullet"><list-item><p>One sample t-test comparing Constant and mutant <italic>IDH</italic> groups:<list list-type="bullet"><list-item><p>Constant vs. <italic>IDH1<sup>R132C/G</sup></italic></p></list-item><list-item><p>Constant vs. <italic>IDH2<sup>mutant</sup></italic> (grouped)</p></list-item><list-item><p>Constant vs. <italic>IDH1/2<sup>mutant </sup></italic>(grouped)</p></list-item></list></p></list-item></list></sec><sec id="s2-6-3"><title>Power calculations</title><p>Power calculations were performed using R software version 3.2.2 and G*Power (version 3.1.7) (<xref ref-type="bibr" rid="bib4">Faul et al., 2007</xref>). Bonferroni corrected one-sample <italic>t</italic>-tests compared to. 01 (threshed as reported by original authors).</p><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Constant</th><th>Group</th><th>Effect size <italic>d</italic></th><th>A priori power</th><th>Group sample size</th></tr></thead><tbody><tr><td>0.01</td><td>IDH1<sup>R132C/G</sup></td><td>8.404</td><td>99.99%</td><td>4</td></tr><tr><td>0.01</td><td>IDH2<sup>Mutant</sup></td><td>6.746</td><td>99.99%</td><td>4</td></tr><tr><td>0.01</td><td>IDH1/2<sup>Mutant</sup></td><td>4.361</td><td>99.99%</td><td>4</td></tr></tbody></table></table-wrap><list list-type="bullet"><list-item><p>Because of the inherent complications that can occur when using primary patient cell lines, we have adjusted our sample size to four samples/group even though we achieve &gt;90% power when using three samples/group.</p></list-item></list></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The Reproducibility Project: Cancer Biology core team would like to thank Courtney Soderberg at the Center for Open Science for assistance with statistical analyses. We would also like to thank Kermit L. Carraway III, Kacey Vandervorst, and Jason Hatakeyama from the Department of Biochemistry and Molecular Medicine at UC Davis and the UC Davis Comprehensive Cancer Center for methods consultation. The following companies generously donated reagents to the Reproducibility Project: Cancer Biology; American Type and Tissue Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma-Aldrich, and System Biosciences (SBI).</p></ack><sec id="s3" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>OF: West Coast Metabolomics Center is a Science Exchange associated laboratory</p></fn><fn fn-type="conflict" id="conf2"><p>MRS: West Coast Metabolomics Center is a Science Exchange associated laboratory</p></fn><fn fn-type="conflict" id="conf3"><p>The other authors declare that no competing interests exist.</p></fn><fn fn-type="conflict" id="conf4"><p>RP:CB: EI, FT, JL, NP: Employed by and hold shares in Science Exchange Inc.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>OF, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>MRS, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>CES-T, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>RP:CB, Conception and design, Drafting or revising the article</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Kimball</surname><given-names>EH</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Absolute quantitation of intracellular metabolite concentrations by an isotope ratio-based approach</article-title><source>Nature Protocols</source><volume>3</volume><fpage>1299</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.107</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>DW</given-names></name><name><surname>Gross</surname><given-names>S</given-names></name><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Bittinger</surname><given-names>MA</given-names></name><name><surname>Driggers</surname><given-names>EM</given-names></name><name><surname>Fantin</surname><given-names>VR</given-names></name><name><surname>Jang</surname><given-names>HG</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Keenan</surname><given-names>MC</given-names></name><name><surname>Marks</surname><given-names>KM</given-names></name><name><surname>Prins</surname><given-names>RM</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Yen</surname><given-names>KE</given-names></name><name><surname>Liau</surname><given-names>LM</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Su</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cancer-associated IDH1 mutations produce 2-hydroxyglutarate</article-title><source>Nature</source><volume>462</volume><fpage>739</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1038/nature08617</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>TM</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Gunn</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>FE</given-names></name><name><surname>Lomax</surname><given-names>J</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An open investigation of the reproducibility of cancer biology research</article-title><source>eLife</source><volume>3</volume><pub-id pub-id-type="doi">10.7554/eLife.04333</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>A-G</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behavior Research Methods</source><volume>39</volume><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/BF03193146</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueroa</surname><given-names>ME</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Shih</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Bhagwat</surname><given-names>N</given-names></name><name><surname>Vasanthakumar</surname><given-names>A</given-names></name><name><surname>Fernandez</surname><given-names>HF</given-names></name><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Wolniak</surname><given-names>K</given-names></name><name><surname>Peeters</surname><given-names>JK</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Choe</surname><given-names>SE</given-names></name><name><surname>Fantin</surname><given-names>VR</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Löwenberg</surname><given-names>B</given-names></name><name><surname>Licht</surname><given-names>JD</given-names></name><name><surname>Godley</surname><given-names>LA</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name><name><surname>Valk</surname><given-names>PJM</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Melnick</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation</article-title><source>Cancer Cell</source><volume>18</volume><fpage>553</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.11.015</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izquierdo-Garcia</surname><given-names>JL</given-names></name><name><surname>Viswanath</surname><given-names>P</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Chaumeil</surname><given-names>MM</given-names></name><name><surname>Pieper</surname><given-names>RO</given-names></name><name><surname>Phillips</surname><given-names>JJ</given-names></name><name><surname>Ronen</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Metabolic reprogramming in mutant IDH1 glioma cells</article-title><source>PloS One</source><volume>10</volume><elocation-id>e0118781</elocation-id><lpage>16</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0118781</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Reitman</surname><given-names>ZJ</given-names></name><name><surname>Spasojevic</surname><given-names>I</given-names></name><name><surname>Batinic-Haberle</surname><given-names>I</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Schmidt-Kittler</surname><given-names>O</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations</article-title><source>PloS One</source><volume>6</volume><elocation-id>e16812</elocation-id><lpage>16818</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0016812</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juratli</surname><given-names>TA</given-names></name><name><surname>Peitzsch</surname><given-names>M</given-names></name><name><surname>Geiger</surname><given-names>K</given-names></name><name><surname>Schackert</surname><given-names>G</given-names></name><name><surname>Eisenhofer</surname><given-names>G</given-names></name><name><surname>Krex</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas</article-title><source>Neuro-Oncology</source><volume>15</volume><fpage>682</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1093/neuonc/not006</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krell</surname><given-names>D</given-names></name><name><surname>Mulholland</surname><given-names>P</given-names></name><name><surname>Frampton</surname><given-names>AE</given-names></name><name><surname>Krell</surname><given-names>J</given-names></name><name><surname>Stebbing</surname><given-names>J</given-names></name><name><surname>Bardella</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>IDH mutations in tumorigenesis and their potential role as novel therapeutic targets</article-title><source>Future Oncology</source><volume>9</volume><fpage>1923</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.2217/fon.13.143</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname><given-names>R</given-names></name><name><surname>Subramanian</surname><given-names>C</given-names></name><name><surname>Jackowski</surname><given-names>S</given-names></name><name><surname>Rock</surname><given-names>CO</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>14615</fpage><lpage>14620</lpage><pub-id pub-id-type="doi">10.1074/jbc.C112.353946</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Kapoor</surname><given-names>GS</given-names></name><name><surname>Rohle</surname><given-names>D</given-names></name><name><surname>Turcan</surname><given-names>S</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Edwards</surname><given-names>CR</given-names></name><name><surname>Khanin</surname><given-names>R</given-names></name><name><surname>Figueroa</surname><given-names>ME</given-names></name><name><surname>Melnick</surname><given-names>A</given-names></name><name><surname>Wellen</surname><given-names>KE</given-names></name><name><surname>O’Rourke</surname><given-names>DM</given-names></name><name><surname>Berger</surname><given-names>SL</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IDH mutation impairs histone demethylation and results in a block to cell differentiation</article-title><source>Nature</source><volume>483</volume><fpage>474</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1038/nature10860</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pusch</surname><given-names>S</given-names></name><name><surname>Schweizer</surname><given-names>L</given-names></name><name><surname>Beck</surname><given-names>A-C</given-names></name><name><surname>Lehmler</surname><given-names>J-M</given-names></name><name><surname>Weissert</surname><given-names>S</given-names></name><name><surname>Miller AK</surname></name><name><surname>von Deimling</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>D-2-hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma</article-title><source>Acta Neuropathologica Communications</source><volume>2</volume><fpage>19</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/2051-5960-2-19</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="book"><person-group person-group-type="author"><collab>R Core Team</collab></person-group><year iso-8601-date="2015">2015</year><source>R: A Language and Environment for Statistical Computing</source><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><uri xlink:href="https://www.R-project.org">https://www.R-project.org</uri></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Weigert</surname><given-names>O</given-names></name><name><surname>Abel-Wahab</surname><given-names>O</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Weinstock</surname><given-names>DM</given-names></name><name><surname>Sharp</surname><given-names>KA</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production</article-title><source>Oncogene</source><volume>31</volume><fpage>2491</fpage><lpage>2498</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.416</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Schwartz</surname><given-names>GK</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>3804</fpage><lpage>3815</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.435495</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Wise</surname><given-names>DR</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Coller</surname><given-names>HA</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Fantin</surname><given-names>VR</given-names></name><name><surname>Hedvat</surname><given-names>CV</given-names></name><name><surname>Perl</surname><given-names>AE</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Carroll</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>SM</given-names></name><name><surname>Sharp</surname><given-names>KA</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate</article-title><source>Cancer Cell</source><volume>17</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.01.020</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>S-H</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Xiao</surname><given-names>M-T</given-names></name><name><surname>Liu</surname><given-names>L-x</given-names></name><name><surname>Jiang</surname><given-names>W-q</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J-y</given-names></name><name><surname>Bin</surname><given-names>W</given-names></name><name><surname>Frye</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y-h</given-names></name><name><surname>Lei</surname><given-names>Q-y</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name><name><surname>Zhao</surname><given-names>S-m</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases</article-title><source>Cancer Cell</source><volume>19</volume><fpage>17</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.12.014</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Zha</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Lei</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha</article-title><source>Science</source><volume>324</volume><fpage>261</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1126/science.1170944</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.12626.002</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Tyler</surname><given-names>Jessica K</given-names></name><role>Reviewing editor</role><aff id="aff4"><institution>Weill Cornell Medical College</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your work entitled &quot;Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Jessica Tyler as Reviewing Editor and Vivek Malhotra as the Senior Editor.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you perform your study, and then submit your revised submission once the experiments are complete.</p><p>Summary:</p><p>The submitted report plan will replicate the results of the key experiments in Ward et al., 2010, using three protocols to replicate the experiments. Power calculations and confirmatory analysis plans are described. In general the authors have done a great job, and the proposed analyses are appropriate and accurate, but we have the following suggestions:</p><p>Essential revisions:</p><p>1) In the confirmatory analysis plan of the Protocols 2 and 3, One-way ANOVA is followed by planned comparisons using Fisher's LSD and in the corresponding power calcualtions for the t-tests of Protocol 2, a 0.05 α error is used. Fisher's LSD however does not control the family wise error rate (see Hayter, 1986) and it is useful only for the calculation of the effect size d. If that is the same statistical analysis method that was used in the original paper, we would like you to do it, but we would also like you to perform a Bonferroni correction (α = 0.025), as this is superior.</p><p>Anthony J. Hayter. The maximum familywise error rate of fisher's least significant difference test. Journal of the American Statistical Association, 81(396):</p><p>1000-1004, 1986. doi: 10.1080/01621459.1986.10478364.</p><p>2) Rather than combining the <italic>IDH1</italic> mutant and <italic>IDH2</italic> mutant patient samples into a single group (table after “Power calculations” in subheading “Protocol 3: Figure 5C”), it will be useful to also consider them as two separate groups in addition to <italic>IDH1</italic>+<italic>IDH2</italic>, as the difference in subcellular localization may lead to differences in D2HG abundance, and it would be worth knowing if there are differences in <italic>IDH1</italic> mutants vs. <italic>IDH2</italic> mutants, in addition to control comparisons. This would obviously change the statistical comparison needed to analyze the data.</p><p>For your interest, we wanted to communicate to you some insightful suggestions that the reviewers had to improve the impact of the findings of the analyses beyond the original study. We appreciate that that is not the intent of the reproduction goal of the Registered report, but we include those ideas here as they may be worthy of your consideration for increasing the impact of this study and/or your future work:</p><p>1) It may be useful to include <italic>IDH2 <sup>R140Q</sup></italic> mutants in the cell based studies, as it is likely that some AML patient samples will harbor that specific mutation.</p><p>2) An estimation of non-<italic>IDH1,2</italic>-formed 2-HG levels would be useful.</p><p>3) Distinction between the R and S chiral forms of 2-HG would be useful.</p><p>4) Concerning the Protocol 1, i.e. replication of the Figure 2 experiments from the original article, this test represents biochemical assays of somewhat &quot;reconstituted&quot; WT or mutant <italic>IDH2</italic> forms and is of the appropriate design. The design could be improved only by a few variations of the overexpressed <italic>IDH2</italic>, either WT or mutant, to better correlate the possible variations due to the different levels of expression between WT or mutant. The statistics to be performed is sufficient to encompass the quality of the data and results even if the overexpression strength is not varied.</p><p>5) Concerning the Protocol 2, i.e. replication of the Figure 3 experiments there is a problem whether &quot;mere reproducibility&quot; is tested or whether a scientific design of this experiment is to be scrutinized. In the former case, assessment is similar as for the Protocol 1. In the latter case however, the experimental design cannot exclude the possibility that WT enzyme does not form 2-HG, since conditions for this counter-Krebs cycle direction of reaction are not set up in the experimental design. Actually such conditions were set up if 2-HG was assayed in experiments similar to those in protocol 1, but long-term - where both directions of reaction are assayed in parallel. The Protocol 2 also cannot rule out the possibility, that mutant enzyme occurring under conditions leading to the forward-Krebs cycle direction is as inefficient in synthesizing 2-HG as the WT.</p><p>6) Concerning the Protocol 3, i.e. replication of the Figure 5 experiments analyzing the AML patient samples the precise error-free identification of mutations is the key to good reproducibility. Since this effort should rather mimic a clinical study, you should do the best to maximize the quality of these replication analyses and should substantially increase the number of samples per group. The suggested 4 samples per group are fulfilling a power of 80%, which however only represents a single repeat of the figure from the original publication but not validation of the possible diagnostic testing.</p><p>7) It would potentially be more beneficial to also focus on other aspects related to D or L2HG and <italic>IDHs</italic> such as the effects on epigenetics and the therapeutic potential of targeting 2HG-mediated epigenetic alterations.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.12626.003</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>1) In the confirmatory analysis plan of the Protocols 2 and 3, One-way ANOVA is followed by planned comparisons using Fisher's LSD and in the corresponding power calcualtions for the t-tests of Protocol 2, a 0.05 α error is used. Fisher's LSD however does not control the family wise error rate (see Hayter, 1986) and it is useful only for the calculation of the effect size d. If that is the same statistical analysis method that was used in the original paper, we would like you to do it, but we would also like you to perform a Bonferroni correction (α = 0.025), as this is superior.</italic> </p><p><italic>Anthony J. Hayter. The maximum familywise error rate of fisher's least significant difference test. Journal of the American Statistical Association, 81(396): 1000-1004, 1986. doi: 10.1080/01621459.1986.10478364.</italic> </p><p>With regard to Protocol 2, we agree with the reviewers’ comment on the use of a correction, such as Bonferroni or the modification of LSD by Hayter to control for the MFWER, however as Hayter describes in his 1986 paper, this applies in situations where the ANOVA is unbalanced or with a balanced design with four or more populations. Since the proposed analysis is balanced with three population groups, the LSD is sufficiently conservative and powerful to account for the multiple comparisons in this specific situation. This is further explained by Levin et al., 1994 and discussed in Maxwell and Delaney, 200 (Chapter 5) and Cohen, 2001 (Chapter 12).</p><p>References:</p><p>Levin, J.R., Serline, R.C., &amp; Seaman M.A. (1994). A controlled, powerful multiple-comparison strategy for several situations. Psychological Bulletin, 115, 153-159.</p><p>Maxwell, S.E. &amp; Delaney, H.D. (2004). Designing experiments and analyzing data: a model comparison perspecitive. Lawrence Erlbaum Associates, Mahwah, N.J., 2nd edition.</p><p>Cohen, B.H. (2001). Explaining psychological statistics. John Wiley and Sons, New York, 2nd edition.</p><p>As for Protocol 3, we have clarified this section. We will perform 3 one sample t-tests compared to the constant (a threshold of 0.01(WT) as defined by Ward et al.). The comparisons will be constant vs. <italic>IDH1</italic> mutant, constant vs. <italic>IDH2</italic> mutant, and constant vs. <italic>IDH1/2</italic> pooled mutants.</p><p><italic>2) Rather than combining the IDH1 mutant and IDH2 mutant patient samples into a single group (table after “Power calculations” in subheading “Protocol 3: Figure 5C”), it will be useful to also consider them as two separate groups in addition to IDH1+IDH2, as the difference in subcellular localization may lead to differences in D2HG abundance, and it would be worth knowing if there are differences in IDH1 mutants vs. IDH2 mutants, in addition to control comparisons. This would obviously change the statistical comparison needed to analyze the data.</italic></p><p>We apologize for the confusion here. There was a typo in the table. Only <italic>IDH2</italic> mutants will be combined for all analyses because of the likely low percentage of samples that will harbor the <italic>IDH2<sup>R172</sup></italic> allele. Further we plan on combining all IDH mutation and compare them to WT. With regard to the <italic>IDH1</italic> vs. <italic>IDH2</italic> mutants, because the Ward et al. paper never made these comparisons this analysis would be outside of the scope of the proposal. However, all data from this project will be made publically available to allow for further exploratory analysis such as this.</p><p><italic>For your interest, we wanted to communicate to you some insightful suggestions that the reviewers had to improve the impact of the findings of the analyses beyond the original study. We appreciate that that is not the intent of the reproduction goal of the Registered report, but we include those ideas here as they may be worthy of your consideration for increasing the impact of this study and/or your future work:</italic></p><p><italic>1) It may be useful to include IDH2 <sup>R140Q</sup> mutants in the cell based studies, as it is likely that some AML patient samples will harbor that specific mutation.</italic> </p><p>We apologize if this was not made clear initially. Any <italic>IDH2 <sup>R140Q</sup></italic> mutants that are identified in our sampling will be included in the replication of original Figure 5C. An addition has been made to the Sampling section of Protocol 3 to clarify this.</p><p> <italic>2) An estimation of non-IDH1,2-formed 2-HG levels would be useful.</italic> </p><p>We agree with the reviewers that this would be an interesting investigation. While outside of the scope of this specific project, all data from GC-MS will be made publically available to allow for further exploratory analysis.</p><p> <italic>3) Distinction between the R and S chiral forms of 2-HG would be useful.</italic> </p><p>We agree with the reviewers that this would be an interesting investigation. While outside of the scope of this specific project, all data from GC-MS will be made publically available to allow for further exploratory analysis.</p><p><italic>4) Concerning the Protocol 1, i.e. replication of the Figure 2 experiments from the original article, this test represents a biochemical assays of somewhat &quot;reconstituted&quot; WT or mutant IDH2 forms and is of the appropriate design. The design could be improved only by a few variations of the overexpressed IDH2, either WT or mutant, to better correlate the possible variations due to the different levels of expression between WT or mutant. The statistics to be performed is sufficient to encompass the quality of the data and results even if the overexpression strength is not varied.</italic> </p><p>We agree that investigating the dose dependent impact of <italic>IDH</italic> overexpression on NADP-NADPH and NADPH-NADP would be interesting, however it is outside of the scope of this project as the original authors did not perform this experiment.</p><p><italic>5) Concerning the Protocol 2, i.e. replication of the Figure 3 experiments there is a problem whether &quot;mere reproducibility&quot; is tested or whether a scientific design of this experiment is to be scrutinized. In the former case, assessment is similar as for the Protocol 1. In the latter case however, the experimental design cannot exclude the possibility that WT enzyme does not form 2-HG, since conditions for this counter-Krebs cycle direction of reaction are not set up in the experimental design. Actually such conditions were set up if 2-HG was assayed in experiments similar to those in protocol 1, but long-term - where both directions of reaction are assayed in parallel. The Protocol 2 also cannot rule out the possibility, that mutant enzyme occurring under conditions leading to the forward-Krebs cycle direction is as inefficient in synthesizing 2-HG as the WT.</italic> </p><p>We agree with the reviewers that this could be the case and we have done our best to design the experiments detailed in this protocol to be a “direct” replication. Study design is always an aspect to be investigated but like the other analyses, all data will be made public so that future analyses can take into account these aspects.</p><p><italic>6) Concerning the Protocol 3, i.e. replication of the Figure 5 experiments analyzing the AML patient samples the precise error-free identification of mutations is the key to good reproducibility. Since this effort should rather mimic a clinical study, you should do the best to maximize the quality of these replication analyses and should substantially increase the number of samples per group. The suggested 4 samples per group are fulfilling a power of 80%, which however only represents a single repeat of the figure from the original publication but not validation of the possible diagnostic testing.</italic> </p><p>We understand the reviewers’ concerns about identification of mutational status and believe this has essential clinical implications. Here, our replication attempt is meant specifically to address the difference in 2HG/glutamate in <italic>IDH</italic> mutants vs. controls as reported in the original paper and not necessarily to investigate the precision of using 2HG/glutamate to identify <italic>IDH</italic> mutations, which we agree would require a larger sample size. The cell lines that we are obtaining are Roswell Park Cancer Institute and mutations have been confirmed multiple times on different platforms. Based on our power analyses, 4 samples should achieve 99% power to detect the published differences in 2HG/glutamate between WT and mutant <italic>IDH</italic>, as the effect size is quite large. Please keep in mind that the scale of Figure 5C is logarithmic.</p><p><italic>7) It would potentially be more beneficial to also focus on other aspects related to D or L2HG and IDHs such as the effects on epigenetics and the therapeutic potential of targeting 2HG-mediated epigenetic alterations.</italic></p><p>We agree that these are interesting avenues of investigation, however, they are outside of the scope of this project.</p></body></sub-article></article>